Electromagnetic fields in the treatment of chronic lower back pain in patients with degenerative disc disease

Aim: To examine the effects of low-amplitude, low frequency electromagnetic field therapy (EMF) therapy in patients with persistent chronic lower back pain associated with degenerative disc disease. Design: Double-blind, randomized and placebo controlled. Intervention: EMF using a medical device resonator; control group underwent same procedures, except the device was turned off. Outcome measures: Pain reduction and mobility. Results: Improvements in overall physical health, social functioning and reduction in bodily pain were observed in the EMF group. The pain relief rating scale showed a higher level of pain relief at the target area in the EMF group. An increase in left lateral mobility was seen only in the EMF group. Conclusion: EMF treatment may be of benefit to patients with chronic nonresponsive lower back pain associated with degenerative disc disease.

Lay abstract: In this preliminary study, we examined the possible value of using a medical device that generates low energy electromagnetic fields for reducing pain and increasing movement in individuals with persistent lower back pain associated with degeneration of the discs of the spine. After five treatment sessions (each lasting 1 h) over a 2-week period, it was found that as compared with those individuals that were not exposed, low energy electromagnetic fields at the pain area may not only improve physical functioning, but also may reduce pain.

First draft submitted: 17 December 2015; Accepted for publication: 25 January 2016; Published online: 11 February 2016

Keywords: alternative and complimentary medicine • biotechnology • pain

It has been estimated that up to 84% of adults have low back pain at some point during their lives [1,2]. Intervertebral disc degeneration is a disease of the discs connecting adjoining vertebrae in which structural damage leads to degeneration of the disc and surrounding area [3]. The degeneration of the disc is considered to be a normal process of aging, but can accelerate or be precipitated by other factors [3]. Degenerative disc disease is a strong etiologic risk factor of chronic low back pain (LBP) [4]. Although a number of pharmacological treatment options are available for pain management, the occurrence of side effects, tolerance, noncompliance and contraindications have raised concerns over their use in some patients with LBP due to degenerative disc disease [5]. On the other hand, a number of nonpharmacological therapies for LBP have been employed [6]. In this regard, therapies with evidence of moderate efficacy for chronic or subacute low back pain were suggested to be cognitive-behavioral therapy, exercise, spinal manipulation and interdisciplinary rehabilitation [6]. While for acute low back pain, the only therapy with evidence of efficacy was suggested to be superficial heat [6]. However, electromagnetic field therapy (EMF) has now also emerged...
as an alternative, safe and effective treatment option for chronic pain in different clinical settings [7–10].

Presently, there is a paucity of information available in the literature that describes the clinical utility of very low EMF in the treatment of chronic LBP associated with degenerative disc disease. Accordingly, in this pilot study, a placebo-controlled, randomized, double-blind study design was employed to assess the efficacy and safety of low-amplitude/low-frequency EMF in the management of nonresponsive chronic LBP and functional capacity in patients with some degenerative disc disease. In addition, quality of life scores as well as mobility measurements were collected to further assess effectiveness of EMF in this cohort of subjects.

**Patients & methods**

**Subject recruitment**

Twenty one subjects were referred to participate in the study through family physicians, physical medicine and rehabilitation, sports medicine, orthopedics and rheumatology departments from the Health Sciences Centre, Winnipeg, Manitoba. The protocol was approved by the institutional review committee. Subjects were male and female, over 25 years of age who had documented chronic LBP persisting more than 6 months, which was not responsive to conservative therapy, MRI radiographic confirmation of diagnosis (minimum 25% and maximum 75% degeneration, and loss of some disc height) and no herniation. In these subjects, the disc degeneration resulted in discogenic low back pain (due to inflammation and abnormal micromotion instability [11]. In order to minimize confounds and to allow for a stringent study design, several exclusion criteria were applied. Exclusion criteria did not allow for the enrollment of patients with bone-on-bone cases, subjects taking steroids, weighing more than 210 lbs, subjects with pacemakers or with metallic prostheses, pregnancies or with epilepsy, diabetes, uncontrolled high blood pressure, history of congestive heart failure and/or cardiac arrhythmias, stroke, heart valve defects, thyroid conditions, subjects at risk of transient ischemic attacks, blood clots or aneurysms, subjects with past history of major head trauma or brain surgery and subjects with chronic low back pain due to sciatica.

**Subject randomization**

Patients were randomly assigned to either the control (n = 7) or EMF treatment (n = 14) arm. Randomization was carried out by the subject drawing an envelope containing a preassigned number. The envelope was handed unopened to the operator of the device. The operator of the device opened the envelope in the control room where no other persons involved in the study were present. Inserts of envelopes containing even numbers were assigned to the treatment arm, whereas inserts

| Magnetic field amplitude (G) | Frequency (Hz) | Duration (minutes) |
|-----------------------------|----------------|-------------------|
| $3.3 \times 10^{-8}$ G      | 0.92           | 15                |
| $2.74 \times 10^{-7}$ G     | 7.7            | 12                |
| $3.43 \times 10^{-7}$ G     | 9.6            | 10                |
| $3.3 \times 10^{-8}$ G      | 0.92           | 23                |

G: Gauss; Hz: Hertz.

Fig. 1. Medical Device Resonator, showing (A) the Helmholtz coil and (B) signal generator. The Medical Device Resonator has Health Canada License and CE Mark (#2001010303CPON0318) and was developed using defined physical principles for electromagnetic field therapy production.
of envelopes containing odd numbers were assigned to the control arm. Since the device operates in total silence and there are no other indicators of when the device is on or off, the study was blinded for the patient, and the clinical assistant doing the positioning of the patient. Subsequent visits to the center remained blind as only the operator of the device had the record of what the previously assigned subject number was and which arm of the study the subject was in.

**Intervention & study design**

The magnetic fields to be used in this pilot study were generated by a medical device resonator. This resonator is a noninvasive device that does not utilize ionizing radiation and produces a uniform low-amplitude/low-frequency EMF through a Helmholtz coil (Figure 1A) operated through a signal generator (Figure 1B). The coil was positioned over the treatment area of the individual lying in horizontal position. This device has a Health Canada license and is listed as an approved device. Subjects assigned to the treatment group were exposed to EMF for 1 h according to the values defined in the Pattern Protocol (Table 1). Subjects in the treatment group were exposed to five treatment sessions (visit 2 through to visit 6) during a 2-week period, for 60 min per treatment, whereas subjects assigned to the placebo group, underwent all procedures, as the treatment arm, except that the device remained off during the session. We selected a room that was not close to items that generate significant environmental fields, such elevators, heating, ventilation and air conditioning (HVAC) systems, and electrical panels. Each subject rated their pain level before and after each treatment, 1 week and 1 month after the last treatment. Accordingly, post-treatment evaluation was conducted at visit 7 and visit 8 at the 5th and 9th week of the study period. Participants underwent a demographic questionnaire, medical history, the Roland Disability Questionnaire and the SF-36 Health Survey at baseline (visit 1, week 1). The Roland Disability Questionnaire and the SF-36 Health Survey were repeated at the end of the study following visit 8. On visits 2 through 8, participants completed the Pain Relief Rating Scale immediately following treatment. Participants completed the McGill Visual Analogue Pain Scale (VAS) and Present Pain Intensity Index before and after treatment on visits 2 through 8. It is pointed out that on visits 7 and 8 the McGill Pain Scales were only measured post-treatment. In addition, measurements of forward mobility (measured from waist to point on mid-upper back), right lateral mobility and left lateral mobility (side to side measure to floor) were obtained before and after treatment on visits 2 through 8. Pain scores were collected through a manual assessment by the subjects by placing a mark on a continuous line between 0 to 10, where 0 = no pain and 10 = worst pain.

### Table 2. Demographic and medical variable comparison of electromagnetic field group and control groups.

| Variable          | EMF            | Control        | p-value |
|-------------------|----------------|----------------|---------|
| Age (years)       | 60.3 (9.7)     | 59.1 (13.4)    | 0.831   |
| Systolic BP (mm Hg)| 120.8 (9.9)    | 122.8 (15.5)   | 0.929   |
| Diastolic BP (mm Hg) | 81.4 (10.0)    | 75.5 (14.7)    | 0.216   |
| Heart rate (beats/min) | 71.9 (11.3)    | 77.0 (11.6)    | 0.387   |

Differences in the demographic and medical variables at baseline between control and EMF groups were determined by using the independent groups t-test for continuous variables. The level of statistical significance was set at p < 0.05.

BP: Blood pressure; EMF: Electromagnetic field therapy.

### Table 3. Roland disability questionnaire changes from baseline to end point.

| Variable          | Baseline median values (first quartile, third quartile) | End point median values (first quartile, third quartile) | p-value |
|-------------------|--------------------------------------------------------|--------------------------------------------------------|---------|
| **Total score**   |                                                        |                                                        |         |
| Control           | 12.0 (8.0, 19.0)                                       | 11.0 (11.0, 17.0)                                       | 0.917   |
| Experimental      | 17.0 (12.0, 21.0)                                      | 17.0 (12.0, 20.0)                                      | 0.195   |
| **Bothersome index** |                                                  |                                                        |         |
| Control           | 6.0 (2.0, 8.0)                                         | 6.0 (1.0, 8.0)                                         | 0.657   |
| Experimental      | 7.0 (2.0, 9.0)                                         | 7.0 (2.0, 8.0)                                         | 0.0733  |

Differences in scores on the Roland Disability Questionnaire between baseline and end point for each group were analyzed by the Wilcoxon matched pairs test on ranks. The level of statistical significance was set at p < 0.05. High scores = poor functioning.
Statistical analysis

Demographic and medical variables at baseline were compared for differences between the two groups using the independent group t-test. Differences in scores on the Roland Disability Questionnaire and SF-36 Health Survey between baseline and end point for each group were analyzed by the Wilcoxon matched pairs test based on ranks. The level of statistical significance was set at \( p < 0.05 \). Scores on the Pain Relief Scale and McGill Visual Analogue Scale for visits 2–8 were graphed in order to represent the pattern across time and between groups. Higher scores = greater pain relief.

EMF: Electromagnetic field therapy.

Table 4. SF-36 health survey changes from baseline to end point.

| Variable                  | Baseline median values (first quartile, third quartile) | End point median values (first quartile, third quartile) | p-value |
|---------------------------|---------------------------------------------------------|----------------------------------------------------------|---------|
| **Control group**         |                                                         |                                                         |         |
| Physical health total score | 47 0 (45.0, 54.0)                                      | 49.0 (47.0, 52.0)                                        | 0.295   |
| Physical functioning      | 20.0 (16.0, 23.0)                                       | 20.0 (15.0, 20.0)                                        | 1.000   |
| Role-physical             | 4.0 (4.0, 5.0)                                          | 4.0 (4.0, 5.0)                                           | 1.000   |
| Bodily pain               | 8.0 (7.0, 9.0)                                          | 7.0 (7.0, 7.0)                                           | 0.173   |
| General health            | 14.0 (14.0, 19.0)                                       | 16.0 (16.0, 22.0)                                        | 0.043   |
| Mental health total score | 44.0 (42.0, 49.0)                                       | 47.0 (46.0, 49.0)                                        | 0.447   |
| Vitality                  | 14.0 (13.0, 19.0)                                       | 16.0 (15.0, 18.0)                                        | 0.590   |
| Social functioning        | 6.0 (4.0, 6.0)                                          | 6.0 (5.0, 7.0)                                           | 0.423   |
| Role-emotional            | 3.0 (3.0, 4.0)                                          | 3.0 (3.0, 5.0)                                           | 1.000   |
| Mental health             | 20.0 (18.0, 23.0)                                       | 20.0 (18.0, 22.0)                                        | 0.686   |
| **EMF group**             |                                                         |                                                         |         |
| Physical health total score | 41.5 (40.0, 45.0)                                      | 43.0 (39.0, 46.0)                                        | 0.929   |
| Physical functioning      | 15.5 (12.0, 18.0)                                       | 16.5 (15.0, 22.0)                                        | 0.022   |
| Role-physical             | 4.0 (4.0, 4.0)                                          | 4.0 (4.0, 5.0)                                           | 0.575   |
| Bodily pain               | 9.0 (8.0, 10.0)                                          | 7.5 (6.0, 9.0)                                           | 0.045   |
| General health            | 13.0 (11.0, 14.0)                                       | 13.0 (10.0, 15.0)                                        | 0.906   |
| Mental health total score | 45.5 (42.0, 49.0)                                       | 46.9 (43.0, 50.0)                                        | 0.753   |
| Vitality                  | 15.5 (11.0, 18.0)                                       | 14.0 (13.0, 16.0)                                        | 0.563   |
| Social functioning        | 6.5 (6.0, 7.0)                                          | 7.0 (6.0, 7.0)                                           | 0.799   |
| Role-emotional            | 4.0 (3.0, 5.0)                                          | 4.0 (3.0, 6.0)                                           | 0.735   |
| Mental health             | 20.5 (19.0, 21)                                         | 20.0 (19.0, 23)                                          | 0.347   |

Differences in scores in the SF-36 Health Survey between baseline and end point for each group were analyzed by the Wilcoxon matched pairs test on ranks. The level of statistical significance was set at \( p <0.05 \). High scores = poor functioning. EMF: Electromagnetic field therapy.

Figure 2. Pain relief rating scale scores for visit 2 through to visit 8 for control and electromagnetic field groups. Scores on the pain relief rating scale for visits 2–8 were graphed in order to represent the pattern across time and between groups. Higher scores = greater pain relief. EMF: Electromagnetic field therapy.
Results

Patient characteristics, RDQ & SF-36 Health Survey

Demographic and medical variable comparison of EMF and control groups is shown in Table 2. It can be seen that there were no differences in age, blood pressure or heart rate between the two groups. The Roland Disability Questionnaire revealed that the EMF and Control groups had similar Total Scores with non-significant differences (Table 3). The SF-36 Health Survey (Table 4) showed a significant improvement in bodily pain (p = 0.045) in the EMF group from baseline to end point.

Pain relief rating scale, McGill VAS & present pain intensity index

The EMF group reported a higher level of ‘pain relief at the target area’ following treatment as compared with the control group on six of the seven visits (Figure 2). Although pain relief scores were similar for the two groups on visit 2, at end point (visit 8) pain relief scores were much higher in the EMF group. The McGill visual analog pain scale measures “the amount of pain recently experienced in the last 48 h.” The EMF group reported a much higher level of pain in the last 48 h (7.1 vs 4.5 on a 10-point scale) than the control group at the initial visit 2 (Figure 3). While the pain scores for the control group increased from the initial value at visit 2 to the final measure at visit 8 (Figure 3A) the pain scores for the EMF group showed the opposite pattern as pain scores decreased from visit 2 to visit 8 (Figure 3B). Indeed, further observation of the data presented in Figure 3 shows not only the progression of changes in the pain scores at each of the study visits, but is also suggestive that the pain relief may persist between visits as well as in the post-treatment period. This is borne out from comparing post-treatment values of the pain scores with the subsequent visit pain scores and comparing the pain score values for both of the post-treatment visits (visits 7 and 8) to the pain score value at the end of the treatment period (visit 6). Furthermore, while the EMF group showed a decrease in pain intensity from baseline to end point, the control group experienced an increase in pain intensity, as measured by the McGill present pain index, from baseline to end point (Figure 4).

Forward & lateral mobility

Figure 5 shows the left lateral mobility for control and EMF groups at baseline and end point. At baseline, the EMF group had less left lateral mobility than the control group, however; the EMF group evidenced an increase in left lateral mobility from baseline to the final end point of the study. Both groups showed little change in forward and right lateral mobility following treatment from visit 2 to visit 8 (data not shown).

Discussion

Several recent commentaries have suggested that EMF treatment may provide moderate benefit in terms of pain relief and/or physical functioning in different pathophysiological conditions [12–16], but no evidence has previously been provided for the use of EMF for treating chronic LBP associated with some disc degenerative disease. Although the sample size of the present study was relatively small, the preliminary results of this pilot study suggest that low energy EMF delivered by
A prototype device (Medical Device Resonator) over a 2-week, five treatment session protocol, has some effect in patients with chronic LBP and physical functioning. Specifically, measures of pain relief at the target area, present pain intensity and pain in the last 48 h in subjects with chronic LBP associated with disc degenerative disease, suggest that EMF treatment may be effective in pain management. Furthermore, from a clinical standpoint, it is apparent that there is a reduction in pain scores in the EMG group of approximately 23% (pretreatment, visit 2 value vs post-treatment, visit 8 value), while an increase in the pain score of approximately 31% (pretreatment, visit 2 value vs post-treatment, visit 8 value) (Figure 3), therefore this difference may be of clinical significance. In this regard, while some authors have suggested a 50% change in VAS/NRS as clinically meaningful changes [17], others suggest a reduction of approximately 30% as clinically significant [18].

The present study also provided suggestive evidence that left lateral mobility increased following EMF treatment compared with the controls. Importantly, in the present study, there were no adverse events or side effects related to the device, treatment or protocol reported. An unexpected finding in our study was that despite a significant reduction in bodily pain, physical functioning was reported to be worse in the EMF group when comparing baseline to end point values. This could be explained on the basis that our study was conducted with a small number of subjects and bias in the questionnaire responses may have occurred, thus impacting on the statistical analysis of the data on physical functioning. Furthermore, it is conceivable that questions asked, with regards to certain daily activities, could have been indicated as difficult to perform even with less back pain. Therefore, a larger study is warranted in order to further validate the findings of the present pilot study and control for accidental biases.

Although EMF in the 150 Gauss (G) range has been used for treatment of chronic low back pain disorders [19], we, employed very low amplitude (3.3 × 10^-8 G to 3.43 × 10^-7 G) and low-frequency (0.92–7.7 Hz) EMF. The selection of the applied signal was based on other studies that have used similar low-amplitude, low-frequency magnetic fields [20–24]. However, it is still unclear which exact frequencies are of benefit and thus a range of frequencies are used. Nonetheless, on the basis of our findings, it can be suggested that such low-amplitude and low-frequency EMF is safe and may also be effective in the treatment of chronic nonresponsive LBP in the post-treatment period and thus could be further developed as a viable alternative for pain management in disc degenerative disease. It is our contention that both frequency and amplitude are equally important to successful field delivery; the energy delivered at the frequencies used in the present study produced beneficial responses. Since the biological systems under examination are sophisticated and dynamic it is likely that the correctness of a field will vary due to the fluctuating spatiotemporal characteristics of the system. The precise mechanisms of beneficial action remain to be fully elucidated, however; many aspects of cell biology as well as the endogenous control of inflammation, healing and bone remodeling have been reported to be modified in response to EMF [10,25–27]. We believe that the EMF exerts a local effect and thus it is conceivable that there is some reduction in inflammation with some healing resulting in reduced transmission of pain signals to the brain, possibilities that need further examination. Indeed, a better understanding of the mechanisms of beneficial
action of EMF could help in identifying patients more likely to benefit from this treatment modality. Furthermore, although humans are continuously exposed to electromagnetic fields, short, controlled exposure to specific electromagnetic fields may exert therapeutic benefits [10].

A limitation of our study is that there were more male subjects in the control group and more female subjects in the EMF group. This imbalance of gender in the groups was a reflection of the randomization process that was undertaken in assigning subjects to the two different groups. While we cannot exclude the possibility that the beneficial effects of EMF in our study may be related to sex, future studies are needed to prove this assumption right or wrong. While the results obtained in the present pilot study are positive in the short term, it is, however; a small study and thus some caution must be exercised in the interpretation of the data obtained. Therefore, a study with a larger patient sample and a long-term (at least 6 months) follow-up period is warranted.

Conclusion
The pilot data suggest that the EMF treatment protocol used in the present study may have clinical relevance and may emerge as a safe and effective adjuvant option in the approach for management of pain in patients with degenerative disc disease.

Acknowledgements
Material support as in use of the equipment (medical device resonator) for the study was provided by Alan Kotowich.

Author contributions
AS Arneja was the lead author of the study and involved in patient diagnosis, selection, recruitment and implementation of the study. A Kotowich provided the Medical Device Resonator for use in the study. D Staley contributed to data presentation and statistical analysis of data. R Summers contributed to statistical analysis of the data. PS Tappia was involved in data compilation and analysis, writing of the manuscript and was corresponding author.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Open access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Executive summary
• A double-blind, randomized, placebo-controlled pilot study was conducted to assess the efficacy of electromagnetic field therapy (EMF) for the management of chronic lower back pain associated with some degenerative disc disease.
• A larger reduction in the total score was observed in the EMF group.
• Overall physical health, social functioning and reduction in bodily pain were observed in the EMF group.
• A higher level of pain relief at the target area was observed in the EMF group.
• Although a decrease in pain intensity was observed in the EMF group, an increase occurred in the control group.
• Left lateral mobility was increased only in the EMF treated group.
• EMF treatment may be of benefit to patients with some degenerative disc disease with chronic nonresponsive lower back pain.

References
Papers of special note have been highlighted as:
• of interest; •• of considerable interest
1 Cassidy JD, Carroll LJ, Côté P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. Spine 23, 1860–1866 (1988).
2 Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine 12, 264–268 (1987).
3 Gopal D, Ho AL, Shah A, Chi JH. Molecular basis of intervertebral disc degeneration. Adv. Exp. Med. Biol. 760, 114–133 (2012).
4 Karppinen J, Shen FH, Luk KD et al. Management of degenerative disk disease and chronic low back pain. Orthop. Clin. North Am. 42, 513–528 (2011).
5 Peniston JH. A review of pharmacotherapy for chronic low back pain with considerations for sports medicine. Phys. Sportsmed. 40, 21–32 (2012).
• Reviews the clinical evidence and the guideline recommendations for pharmacotherapy of chronic lower back pain.
6 Chou R, Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 147, 492–504 (2007).
7 Bjordal JM, Johnson MI, Lopes-Martins RA et al. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomized placebo-controlled trials. BMC Musculoskelet. Disord. 8, 51 (2007).
8 Bökkon I, Till A, Grass F et al. Phantom pain reduction by low-frequency and low-intensity electromagnetic fields. Electromagn. Biol. Med. 30, 115–127 (2011).
9 Vavken P, Arrich F, Schuhfried O, Dorotka R. Effectiveness of pulsed electromagnetic field therapy in the management of osteoarthrits of the knee: a meta-analysis of randomized controlled trials. J. Rheumatol. Med. 41, 406–411 (2009).
10 Markov MS. Electromagnetic fields and life. J. Electr. Electron. Syst. 3, 119 (2014).
• Concise and highly informative review on the diagnostic and therapeutic use of electromagnetic fields in medicine.
11 Zhang YG, Guo TM, Guo X, Wu SX. Clinical diagnosis for discogenic low back pain. Int. J. Biol. Sci. 13, 647–658 (2009).
12 Li S, Yu B, Zhou D et al. Electromagnetic fields for treating osteoarthritis. Cochrane Database Syst. Rev. 12, CD003523 (2013).
13 Negm A, Lorberga A, Macintyre NJ. Efficacy of low frequency pulsed subsensory threshold electrical stimulation vs placebo on pain and physical function in people with knee osteoarthritis: systematic review with meta-analysis. Osteoarthritis Cartilage 21, 1281–1289 (2013).
14 Pilla AA. Nonthermal electromagnetic fields: from first messenger to therapeutic applications. Electromagn. Biol. Med. 32, 123–136 (2013).
15 Ryang We S, Koog YH, Jeong KL, Wi H. Effects of pulsed electromagnetic field on knee osteoarthritis: a systematic review. Rheumatology. 52, 815–824 (2013).
16 Bagnato GL, Miceli G, Marino N et al. Pulsed electromagnetic fields in knee osteoarthrits: a double blind, placebo-controlled, randomized clinical trial. Rheumatology doi:10.1093/rheumatology/kev426 (2015) (Epub ahead of print).
17 Hirschfeld G. Clinically meaningful changes in pain ratings: whey we need special cut points for children and adolescents. Pain Management 4, 81–83 (2014).
18 Farrar JT, Young JP, LaMoreaux L et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149–158 (2001).
19 Harden RN, Remble TA, Houle TT et al. Prospective, randomized, single-blind, sham treatment-controlled study of the safety and efficacy of an electromagnetic field device for the treatment of chronic low back pain: a pilot study. Pain Pract. 7, 248–255 (2007).
• Pilot study reporting that electromagnetic fields may be an effective and safe modality for the treatment of chronic low back pain disorders.
20 Jacobson JL. A look at the possible mechanism and potential of magneto therapy. J. Theor. Biol. 149, 97–119 (1991).
21 Jacobson JL. Jacobson resonance: the coupling mechanism for weak electromagnetic field bioeffects. And a new way to approach magneto therapy. Painminera Med. 36, 34–41 (1994).
• A seminal review that explains the influence on biological systems as well as the therapeutic potential of weak electromagnetic fields.
22 Jacobson JL, Yamanashi WS. A possible, physical mechanism in the treatment of neurologic disorders with externally applied pico Tesla magnetic fields. Physiol. Chem. Phys. Med. NMR 26, 287–297 (1994).
23 Jacobson JL, Gorman R, Yamanashi WS, Saxena BB, Clayton L. Low-amplitude, extremely low frequency magnetic fields for the treatment of osteoarthritic knees: a double-blind clinical study. Altern. Ther. Health Med. 7, 54–64 (2001).
• An excellent study that demonstrates the efficacy of low-amplitude, low-frequency magnetic fields for the treatment of osteoarthritis of the knee.
24 Saxena A, Jacobson J, Yamanashi W, Scherlag B, Lamberth J, Saxena B. A hypothetical mathematical construct explaining the mechanism of biological mplification in an experimental model utilizing pico Tesla (PT) electromagnetic fields. Med. Hypotheses 60, 821–839 (2003).
• An outstanding article describing the influence of very weak, low frequency electromagnetic fields on biological systems.
25 Shupak NM. Therapeutic uses of pulsed magnetic-field exposure: a review. Radio Sci. Bull. 307, 9–32 (2003).
• A succinct review providing cumulative evidence for therapeutic value of electromagnetic field therapy.
26 Bassett CA. Beneficial effects of electromagnetic fields. J. Cell Biochem. 51, 387–393 (1993).
27 Markov MS. Expanding use of pulsed electromagnetic field therapies. Electromagn. Biol. Med. 26, 257–274 (2007).
• A comprehensive and informative review on the clinical utility and safety of electromagnetic fields.